Fig. 3: Drug screening identifies Oxa12 as necroptosis inhibitor in L929 cells.
From: Phenotypic screening identifies a new oxazolone inhibitor of necroptosis and neuroinflammation
a Schematic overview of the drug screening workflow. b Normalized necroptosis inhibition values depicted as percentage of control (DMSO) for compounds (30 µM) tested on L929 cells exposed to 30 µM TNF-α for 8 h. Results are presented as the mean value ± SEM of at least three independent experiments performed in duplicates. c L929 cells were incubated with Oxa12 (0.1 to 50 µM) plus TNF-α (30 µM) for 24 h. d L929 cells were incubated with Oxa12 (1–150 µM) for 24 h. Cell viability was determined by the MTS metabolism. The results are presented as the mean value ± SEM of three independent experiments performed in duplicates and normalized to vehicle control (DMSO)
